Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Teduglutide for the treatment of short bowel syndrome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e4acc3d6924e4953942877685d2313b4,
title = "Teduglutide for the treatment of short bowel syndrome",
abstract = "Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS). Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS. This monograph reviews the preclinical and clinical data that provide the scientific rationale for the use of teduglutide in this orphan condition. Teduglutide increases intestinal absorption and diminishes the need for parenteral support in patients with SBS. The adverse event profile is consistent with the underlying disease and the known mechanism of action of teduglutide. Following its positive regulatory review and approval by the European Medicines Agency and the U.S. Food and Drug Administration in 2012, teduglutide has moved from the research setting to clinical practice, offering a new treatment paradigm for this burdensome and potentially life-threatening condition.",
keywords = "Amino Acid Sequence, Animals, Humans, Molecular Sequence Data, Peptides, Short Bowel Syndrome",
author = "Jeppesen, {P B}",
note = "Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.",
year = "2013",
month = oct,
doi = "10.1358/dot.2013.49.10.2017025",
language = "English",
volume = "49",
pages = "599--614",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "10",

}

RIS

TY - JOUR

T1 - Teduglutide for the treatment of short bowel syndrome

AU - Jeppesen, P B

N1 - Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.

PY - 2013/10

Y1 - 2013/10

N2 - Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS). Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS. This monograph reviews the preclinical and clinical data that provide the scientific rationale for the use of teduglutide in this orphan condition. Teduglutide increases intestinal absorption and diminishes the need for parenteral support in patients with SBS. The adverse event profile is consistent with the underlying disease and the known mechanism of action of teduglutide. Following its positive regulatory review and approval by the European Medicines Agency and the U.S. Food and Drug Administration in 2012, teduglutide has moved from the research setting to clinical practice, offering a new treatment paradigm for this burdensome and potentially life-threatening condition.

AB - Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS). Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS. This monograph reviews the preclinical and clinical data that provide the scientific rationale for the use of teduglutide in this orphan condition. Teduglutide increases intestinal absorption and diminishes the need for parenteral support in patients with SBS. The adverse event profile is consistent with the underlying disease and the known mechanism of action of teduglutide. Following its positive regulatory review and approval by the European Medicines Agency and the U.S. Food and Drug Administration in 2012, teduglutide has moved from the research setting to clinical practice, offering a new treatment paradigm for this burdensome and potentially life-threatening condition.

KW - Amino Acid Sequence

KW - Animals

KW - Humans

KW - Molecular Sequence Data

KW - Peptides

KW - Short Bowel Syndrome

U2 - 10.1358/dot.2013.49.10.2017025

DO - 10.1358/dot.2013.49.10.2017025

M3 - Journal article

C2 - 24191254

VL - 49

SP - 599

EP - 614

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 10

ER -

ID: 42486355